FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:PTK2-PHF20L1

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: PTK2-PHF20L1
FusionPDB ID: 70048
FusionGDB2.0 ID: 70048
HgeneTgene
Gene symbol

PTK2

PHF20L1

Gene ID

5747

51105

Gene nameprotein tyrosine kinase 2PHD finger protein 20 like 1
SynonymsFADK|FAK|FAK1|FRNK|PPP1R71|p125FAK|pp125FAKCGI-72|TDRD20B|URLC1
Cytomap

8q24.3

8q24.22

Type of geneprotein-codingprotein-coding
Descriptionfocal adhesion kinase 1FADK 1FAK-related non-kinase polypeptidePTK2 protein tyrosine kinase 2focal adhesion kinase isoform FAK-Del33focal adhesion kinase-related nonkinaseprotein phosphatase 1 regulatory subunit 71PHD finger protein 20-like protein 1tudor domain containing 20Btudor domain-containing protein PHF20L1up-regulated in lung cancer 1
Modification date2020032720200320
UniProtAcc..
Ensembl transtripts involved in fusion geneENST idsENST00000340930, ENST00000395218, 
ENST00000517887, ENST00000519419, 
ENST00000521059, ENST00000522684, 
ENST00000535192, ENST00000430260, 
ENST00000519465, ENST00000538769, 
ENST00000517712, ENST00000519635, 
ENST00000519881, ENST00000520151, 
ENST00000520892, ENST00000522950, 
ENST00000220847, ENST00000395390, 
ENST00000337920, ENST00000395376, 
ENST00000395379, ENST00000395386, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score39 X 32 X 15=187208 X 9 X 7=504
# samples 5710
** MAII scorelog2(57/18720*10)=-5.03747470541866
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(10/504*10)=-2.33342373372519
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: PTK2 [Title/Abstract] AND PHF20L1 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: PTK2 [Title/Abstract] AND PHF20L1 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)PTK2(141684396)-PHF20L1(133858025), # samples:1
PTK2(141874410)-PHF20L1(133836248), # samples:1
Anticipated loss of major functional domain due to fusion event.PTK2-PHF20L1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
PTK2-PHF20L1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
PTK2-PHF20L1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
PTK2-PHF20L1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
PTK2-PHF20L1 seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF.
PTK2-PHF20L1 seems lost the major protein functional domain in Hgene partner, which is a kinase due to the frame-shifted ORF.
PTK2-PHF20L1 seems lost the major protein functional domain in Tgene partner, which is a epigenetic factor due to the frame-shifted ORF.
PTK2-PHF20L1 seems lost the major protein functional domain in Tgene partner, which is a essential gene due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgenePTK2

GO:0007179

transforming growth factor beta receptor signaling pathway

24036928

HgenePTK2

GO:0007229

integrin-mediated signaling pathway

24036928

HgenePTK2

GO:0010763

positive regulation of fibroblast migration

26763945

HgenePTK2

GO:0018108

peptidyl-tyrosine phosphorylation

10655584|11331870

HgenePTK2

GO:0022408

negative regulation of cell-cell adhesion

21703394

HgenePTK2

GO:0030335

positive regulation of cell migration

11331870|21703394

HgenePTK2

GO:0033628

regulation of cell adhesion mediated by integrin

10655584

HgenePTK2

GO:0046777

protein autophosphorylation

10655584|11331870

HgenePTK2

GO:0048013

ephrin receptor signaling pathway

10655584

HgenePTK2

GO:0060396

growth hormone receptor signaling pathway

10925297

HgenePTK2

GO:0090303

positive regulation of wound healing

26763945



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr8:141684396/chr8:133858025)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across PTK2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across PHF20L1 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000522684PTK2chr8141684396-ENST00000395386PHF20L1chr8133858025+596629392303022930
ENST00000395218PTK2chr8141684396-ENST00000395386PHF20L1chr8133858025+599629692303052940
ENST00000340930PTK2chr8141684396-ENST00000395386PHF20L1chr8133858025+592128941552977940
ENST00000519419PTK2chr8141684396-ENST00000395386PHF20L1chr8133858025+618031532703236988
ENST00000430260PTK2chr8141684396-ENST00000395386PHF20L1chr8133858025+412410974251180251

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000522684ENST00000395386PTK2chr8141684396-PHF20L1chr8133858025+0.0001939640.9998061
ENST00000395218ENST00000395386PTK2chr8141684396-PHF20L1chr8133858025+0.0001865890.9998134
ENST00000340930ENST00000395386PTK2chr8141684396-PHF20L1chr8133858025+0.00018920.9998109
ENST00000519419ENST00000395386PTK2chr8141684396-PHF20L1chr8133858025+0.0001805790.99981946
ENST00000430260ENST00000395386PTK2chr8141684396-PHF20L1chr8133858025+0.0025463470.99745363

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for PTK2-PHF20L1

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
PTK2chr8141684396PHF20L1chr81338580251097224LSSPADSYNEGVKFWKAGLISQGSWS
PTK2chr8141684396PHF20L1chr81338580252894913LSSPADSYNEGVKFWKAGLISQGSWS
PTK2chr8141684396PHF20L1chr81338580252939903LSSPADSYNEGVKFWKAGLISQGSWS
PTK2chr8141684396PHF20L1chr81338580252969913LSSPADSYNEGVKFWKAGLISQGSWS
PTK2chr8141684396PHF20L1chr81338580253153961LSSPADSYNEGVKFWKAGLISQGSWS

Top

Potential FusionNeoAntigen Information of PTK2-PHF20L1 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
PTK2-PHF20L1_141684396_133858025.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
PTK2-PHF20L1chr8141684396chr81338580252894HLA-B45:01NEGVKFWKA0.9930.8851817
PTK2-PHF20L1chr8141684396chr81338580252894HLA-B50:02NEGVKFWKA0.98790.5096817
PTK2-PHF20L1chr8141684396chr81338580252894HLA-A32:13SYNEGVKFW0.98770.9368615
PTK2-PHF20L1chr8141684396chr81338580252894HLA-B58:02SYNEGVKFW0.97070.8394615
PTK2-PHF20L1chr8141684396chr81338580252894HLA-B58:02DSYNEGVKFW0.9950.6812515
PTK2-PHF20L1chr8141684396chr81338580252894HLA-B57:03ADSYNEGVKF0.98150.862414
PTK2-PHF20L1chr8141684396chr81338580252894HLA-B15:17ADSYNEGVKF0.92020.8281414
PTK2-PHF20L1chr8141684396chr81338580252894HLA-C04:10SYNEGVKF0.99650.6103614
PTK2-PHF20L1chr8141684396chr81338580252894HLA-C07:10SYNEGVKF0.99490.9484614
PTK2-PHF20L1chr8141684396chr81338580252894HLA-C07:67SYNEGVKF0.99450.9184614
PTK2-PHF20L1chr8141684396chr81338580252894HLA-C07:80SYNEGVKF0.99450.9184614
PTK2-PHF20L1chr8141684396chr81338580252894HLA-C07:19SYNEGVKF0.99330.6762614
PTK2-PHF20L1chr8141684396chr81338580252894HLA-C07:27SYNEGVKF0.99130.9376614
PTK2-PHF20L1chr8141684396chr81338580252894HLA-C04:14SYNEGVKF0.98950.6734614
PTK2-PHF20L1chr8141684396chr81338580252894HLA-B15:31DSYNEGVKF0.97990.7756514
PTK2-PHF20L1chr8141684396chr81338580252894HLA-C07:19SYNEGVKFW0.29720.7225615
PTK2-PHF20L1chr8141684396chr81338580252894HLA-C07:95SYNEGVKFW0.25320.7131615
PTK2-PHF20L1chr8141684396chr81338580252894HLA-C07:67SYNEGVKFW0.25250.9397615
PTK2-PHF20L1chr8141684396chr81338580252894HLA-C07:80SYNEGVKFW0.25250.9397615
PTK2-PHF20L1chr8141684396chr81338580252894HLA-C07:10SYNEGVKFW0.23470.9541615
PTK2-PHF20L1chr8141684396chr81338580252894HLA-C07:27SYNEGVKFW0.20520.9436615
PTK2-PHF20L1chr8141684396chr81338580252894HLA-C07:17SYNEGVKF0.99580.9684614
PTK2-PHF20L1chr8141684396chr81338580252894HLA-C18:01SYNEGVKF0.9950.6419614
PTK2-PHF20L1chr8141684396chr81338580252894HLA-C07:02SYNEGVKF0.99450.9184614
PTK2-PHF20L1chr8141684396chr81338580252894HLA-C06:06SYNEGVKF0.98850.9881614
PTK2-PHF20L1chr8141684396chr81338580252894HLA-C04:04SYNEGVKF0.98450.7862614
PTK2-PHF20L1chr8141684396chr81338580252894HLA-C14:02SYNEGVKF0.96290.9463614
PTK2-PHF20L1chr8141684396chr81338580252894HLA-C14:03SYNEGVKF0.96290.9463614
PTK2-PHF20L1chr8141684396chr81338580252894HLA-A25:01DSYNEGVKF0.99730.7225514
PTK2-PHF20L1chr8141684396chr81338580252894HLA-B35:24DSYNEGVKF0.99640.7665514
PTK2-PHF20L1chr8141684396chr81338580252894HLA-B35:20DSYNEGVKF0.97140.8206514
PTK2-PHF20L1chr8141684396chr81338580252894HLA-B35:11DSYNEGVKF0.93380.7794514
PTK2-PHF20L1chr8141684396chr81338580252894HLA-B58:06SYNEGVKFW0.82360.6732615
PTK2-PHF20L1chr8141684396chr81338580252894HLA-B18:04DSYNEGVKF0.81670.891514
PTK2-PHF20L1chr8141684396chr81338580252894HLA-B15:13SYNEGVKFW0.68680.5298615
PTK2-PHF20L1chr8141684396chr81338580252894HLA-B35:43DSYNEGVKF0.6730.7504514
PTK2-PHF20L1chr8141684396chr81338580252894HLA-B18:07DSYNEGVKF0.61530.8515514
PTK2-PHF20L1chr8141684396chr81338580252894HLA-C07:17SYNEGVKFW0.2630.9647615
PTK2-PHF20L1chr8141684396chr81338580252894HLA-C07:02SYNEGVKFW0.25250.9397615
PTK2-PHF20L1chr8141684396chr81338580252894HLA-C07:01SYNEGVKFW0.21890.6803615
PTK2-PHF20L1chr8141684396chr81338580252894HLA-C07:22SYNEGVKFW0.19750.7187615
PTK2-PHF20L1chr8141684396chr81338580252894HLA-C14:03SYNEGVKFW0.03860.9318615
PTK2-PHF20L1chr8141684396chr81338580252894HLA-C14:02SYNEGVKFW0.03860.9318615
PTK2-PHF20L1chr8141684396chr81338580252894HLA-C06:06SYNEGVKFW0.01480.9804615
PTK2-PHF20L1chr8141684396chr81338580252894HLA-C06:17SYNEGVKFW0.01030.9865615
PTK2-PHF20L1chr8141684396chr81338580252894HLA-C06:02SYNEGVKFW0.01030.9865615
PTK2-PHF20L1chr8141684396chr81338580252894HLA-A25:01DSYNEGVKFW0.97610.8225515

Top

Potential FusionNeoAntigen Information of PTK2-PHF20L1 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
PTK2-PHF20L1_141684396_133858025.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-0103NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1457NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1501NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1501YNEGVKFWKAGLISQ722
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1502NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1503NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1503YNEGVKFWKAGLISQ722
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1504NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1504YNEGVKFWKAGLISQ722
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1504EGVKFWKAGLISQGS924
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1505NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1505YNEGVKFWKAGLISQ722
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1506NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1506YNEGVKFWKAGLISQ722
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1507NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1507YNEGVKFWKAGLISQ722
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1508NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1509NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1509YNEGVKFWKAGLISQ722
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1510NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1510YNEGVKFWKAGLISQ722
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1510EGVKFWKAGLISQGS924
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1510SYNEGVKFWKAGLIS621
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1512NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1512YNEGVKFWKAGLISQ722
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1512SYNEGVKFWKAGLIS621
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1513NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1513YNEGVKFWKAGLISQ722
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1514NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1515NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1516NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1516YNEGVKFWKAGLISQ722
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1518NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1518YNEGVKFWKAGLISQ722
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1518EGVKFWKAGLISQGS924
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1518SYNEGVKFWKAGLIS621
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1519NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1520NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1520YNEGVKFWKAGLISQ722
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1521NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1521YNEGVKFWKAGLISQ722
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1521EGVKFWKAGLISQGS924
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1521SYNEGVKFWKAGLIS621
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1522NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1522YNEGVKFWKAGLISQ722
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1523NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1523YNEGVKFWKAGLISQ722
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1524NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1524YNEGVKFWKAGLISQ722
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1526NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1528NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1528YNEGVKFWKAGLISQ722
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1528EGVKFWKAGLISQGS924
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1529NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1530NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1531NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1532NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1532YNEGVKFWKAGLISQ722
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1533NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1533YNEGVKFWKAGLISQ722
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1535NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1535YNEGVKFWKAGLISQ722
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1536NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1536YNEGVKFWKAGLISQ722
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1537NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1537YNEGVKFWKAGLISQ722
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1537EGVKFWKAGLISQGS924
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1537SYNEGVKFWKAGLIS621
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1538NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1539NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1540NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1540YNEGVKFWKAGLISQ722
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1541NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1541YNEGVKFWKAGLISQ722
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1542NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1542YNEGVKFWKAGLISQ722
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1543NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1543YNEGVKFWKAGLISQ722
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1544NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1545NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1545YNEGVKFWKAGLISQ722
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1546NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1546YNEGVKFWKAGLISQ722
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1547NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1548NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1548YNEGVKFWKAGLISQ722
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1549NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1549YNEGVKFWKAGLISQ722
PTK2-PHF20L1chr8141684396chr81338580252894DRB1-1615NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB5-0103NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB5-0106NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB5-0202NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB5-0202YNEGVKFWKAGLISQ722
PTK2-PHF20L1chr8141684396chr81338580252894DRB5-0203NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB5-0204NEGVKFWKAGLISQG823
PTK2-PHF20L1chr8141684396chr81338580252894DRB5-0204YNEGVKFWKAGLISQ722
PTK2-PHF20L1chr8141684396chr81338580252894DRB5-0204EGVKFWKAGLISQGS924
PTK2-PHF20L1chr8141684396chr81338580252894DRB5-0204SYNEGVKFWKAGLIS621
PTK2-PHF20L1chr8141684396chr81338580252894DRB5-0205NEGVKFWKAGLISQG823

Top

Fusion breakpoint peptide structures of PTK2-PHF20L1

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
9205SYNEGVKFWKAGLIPTK2PHF20L1chr8141684396chr81338580252894

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of PTK2-PHF20L1

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN9205SYNEGVKFWKAGLI-6.7759-6.8893
HLA-B14:023BVN9205SYNEGVKFWKAGLI-4.69541-5.73071
HLA-B52:013W399205SYNEGVKFWKAGLI-7.29079-7.40419
HLA-B52:013W399205SYNEGVKFWKAGLI-4.68863-5.72393
HLA-A24:025HGA9205SYNEGVKFWKAGLI-6.91369-7.94899
HLA-A24:025HGA9205SYNEGVKFWKAGLI-5.33553-5.44893
HLA-B44:053DX89205SYNEGVKFWKAGLI-8.15615-8.26955
HLA-B44:053DX89205SYNEGVKFWKAGLI-4.08952-5.12482

Top

Vaccine Design for the FusionNeoAntigens of PTK2-PHF20L1

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
PTK2-PHF20L1chr8141684396chr8133858025414ADSYNEGVKFGCTGACAGCTACAACGAGGGTGTCAAGTTC
PTK2-PHF20L1chr8141684396chr8133858025514DSYNEGVKFGACAGCTACAACGAGGGTGTCAAGTTC
PTK2-PHF20L1chr8141684396chr8133858025515DSYNEGVKFWGACAGCTACAACGAGGGTGTCAAGTTCTGG
PTK2-PHF20L1chr8141684396chr8133858025614SYNEGVKFAGCTACAACGAGGGTGTCAAGTTC
PTK2-PHF20L1chr8141684396chr8133858025615SYNEGVKFWAGCTACAACGAGGGTGTCAAGTTCTGG
PTK2-PHF20L1chr8141684396chr8133858025817NEGVKFWKAAACGAGGGTGTCAAGTTCTGGAAAGCT

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
PTK2-PHF20L1chr8141684396chr8133858025621SYNEGVKFWKAGLISAGCTACAACGAGGGTGTCAAGTTCTGGAAAGCTGGCTTGATTTCA
PTK2-PHF20L1chr8141684396chr8133858025722YNEGVKFWKAGLISQTACAACGAGGGTGTCAAGTTCTGGAAAGCTGGCTTGATTTCACAG
PTK2-PHF20L1chr8141684396chr8133858025823NEGVKFWKAGLISQGAACGAGGGTGTCAAGTTCTGGAAAGCTGGCTTGATTTCACAGGGG
PTK2-PHF20L1chr8141684396chr8133858025924EGVKFWKAGLISQGSGAGGGTGTCAAGTTCTGGAAAGCTGGCTTGATTTCACAGGGGAGT

Top

Information of the samples that have these potential fusion neoantigens of PTK2-PHF20L1

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
OVPTK2-PHF20L1chr8141684396ENST00000340930chr8133858025ENST00000395386TCGA-61-2016

Top

Potential target of CAR-T therapy development for PTK2-PHF20L1

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to PTK2-PHF20L1

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to PTK2-PHF20L1

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource